Individualizing Care for Patients With PIDD: The Role of the Pharmacist in Managing Patients on IVIg and SCIg

This activity was originally presented at the 2023 Asembia Specialty Pharmacy Summit.

Program Description

Primary immunodeficiency disorders (PIDDs) refer to a large heterogeneous group of disorders that result from defects in the development of the immune system and/or function. Timely diagnosis and early treatment interventions are important to alleviate associated complications as well as the health and economic burdens of PIDDs. Immunoglobulin (Ig) replacement has been the backbone of therapy for patients with PIDDs. Intravenous Ig has been routinely used, and the use of subcutaneous Ig is increasing due to flexibility and reduced adverse effects and infusion time. Another important discussion for Ig therapy is the potential convenience of self-administration. Specialty pharmacists must be familiar with the most up-to-date information about intravenous and subcutaneous Ig administration, be able to identify patients who are ideal candidates for one route versus another, and ensure patients are properly educated regarding administration and intervention strategies to improve adherence and quality of life. Through this activity, pharmacists will be equipped to make patient-specific product recommendations, implement shared decision making into treatment planning and management, and educate patients and caregivers about treatment expectations.

Target audience: Specialty pharmacists

Type of activity: Application
Release date: May 17, 2023
Expiration date: May 17, 2024

Time to complete activity: 1.5 hours

Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Determine the clinical burden and quality of life impact of primary immunodeficiency disorder (PIDD) and the role of intravenous (IV) and subcutaneous (SC) immunoglobulin (Ig)
• Examine efficacy and safety data of IVIg and SCIg, as well as differences in administration, dosing, time between infusions, and common adverse effects
• Identify opportunities for pharmacists to improve patient management, coordination of care, and access to treatments for PIDD to reduce the clinical and economic burden

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-204-H01-P. The activity is available for CE credit through May 17, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Amy Ehlers, PharmD, BS, CSP, IgCP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Michelle C. Carlson, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms